149 results
Page 2 of 8
8-K
EX-99.1
3ee3kc95
8 Feb 24
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
7:03am
8-K
EX-99.1
ge71q4qityv
31 Jan 24
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
7:00am
8-K
EX-99.1
tcm0t2sr4cltwnmx1e8p
3 Jan 24
Business Development Update for Shareholders
7:00am
8-K
EX-99.1
hkyume4kb38c
19 Dec 23
Other Events
7:00am
8-K
EX-99.1
s48a6jj4x
18 Dec 23
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
7:00am
424B5
fagr6pqbv hwfr25j
6 Dec 23
Prospectus supplement for primary offering
6:03am
8-K
EX-99.1
thpkjoyx 2xqwhwdk1
29 Nov 23
Other Events
7:00am
424B5
8y2vf4w5
17 Nov 23
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
3r56w
14 Nov 23
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
12:00am
8-K
EX-99.1
zop6qr974ogwx4gfqd
8 Nov 23
Biocardia Reports Third Quarter 2023 Business Highlights and Financial Results
4:08pm
8-K
EX-99.1
hm9gxg1btjvtusmsmv
11 Oct 23
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
6:04am
8-K
EX-99.1
139ch a7xb
6 Sep 23
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
7:15am
8-K
EX-99.1
0u15nl7c9bn6r42yzt8m
5 Sep 23
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
7:15am
8-K
EX-99.1
yar4msl4r7oye08
9 Aug 23
Biocardia Reports Second Quarter 2023 Business Highlights and Financial Results
4:08pm
8-K
EX-99.1
bpdw 2nogmrc
24 Jul 23
Regulation FD Disclosure
7:00am
424B5
ricfn
22 Jun 23
Prospectus supplement for primary offering
8:33am